Ogeda SA
→
Astellas Pharma
Acquisition · Cash + milestone payments · announced Apr 3, 2017
Announced
Apr 3, 2017
Closed
May 17, 2017
Economics
Cash + milestone payments()
Pre-deal · pre-deal mark: 2017, year precision · rounding grid ±$100M · Astellas press release — Ogeda SA acquisition, 2017
EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates
Target
Ogeda SA
Menopause · Clinical / therapeutic
HQ Gosselies, Belgium · Founded 1999
Drug discovery company developing fezolinetant for menopausal vasomotor symptoms; formerly Euroscreen SA
- Astellas Pharma press release (May 17, 2017)
- PR Newswire - Astellas completes acquisition (May 2017)
- Astellas newsroom - newsroom.astellas.com
Acquirer
Astellas Pharma
Healthcare
HQ Tokyo, Japan
Japanese pharmaceutical company focused on urology, oncology, and women's health
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Added fezolinetant (NK3 receptor antagonist) for menopausal vasomotor symptoms — later FDA-approved as VEOZAH in 2023
Evidence ladder
Secondary (press / IR)
Astellas Pharma press release (May 17, 2017)
Secondary (press / IR)
PR Newswire
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- EUR 500M upfront + up to EUR 300M development milestones; ~$560M USD at 2017 exchange rates
- Pre-deal valuation sourced from: Astellas press release — Ogeda SA acquisition, 2017. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Menopause
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
| Why included | ||||
|---|---|---|---|---|
| KaNDy Therapeutics | Bayer | Aug 11, 2020 | same evidence class |
Other verified deals by Astellas Pharma
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Astellas Pharma are already listed above, or none are in the dataset.
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Ogeda SA (Menopause). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.